SCHEMBL23748280

SCHEMBL23748280

C=CCOc1c(Cl)cccc1C(O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR5 P32302 3/20 0.46
ATM Q13315 1/20 0.37
KMT2A Q03164 2/20 0.36
FABP4 P15090 1/20 0.36
FABP5 Q01469 1/20 0.36
DRD2 P14416 1/20 0.36
DRD1 P21728 1/20 0.36
IDO1 P14902 3/20 0.36
TDO2 P48775 3/20 0.36
IDO2 Q6ZQW0 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP2D6 P10635 2/20 0.35
ACP3 P15309 1/20 0.34
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
SLC22A1 O15245 1/20 0.33
LMNA P02545 1/20 0.33
CYP1A2 P05177 1/20 0.33
ADRB2 P07550 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748171 0.84 CXCR5 (0.42) CXCR5ATMKMT2AFABP4FABP5
SCHEMBL23748175 0.83 DRD2 (0.36) CXCR5KMT2ADRD2DRD1IDO1
SCHEMBL23748235 0.78 DRD2 (0.52) KMT2ADRD2DRD1ALDH1A1CYP2D6
SCHEMBL23748221 0.77 HTR2C (0.36) CXCR5DRD2DRD1ALDH1A1CYP2D6
SCHEMBL10648647 0.77 KMT2A (0.47) CXCR5ATMKMT2AALDH1A1MEN1
SCHEMBL23748137 0.74 GAA (0.50) KMT2ADRD2DRD1IDO1TDO2
SCHEMBL23748209 0.74 GAA (0.53) DRD2DRD1ALDH1A1CYP2D6SLC22A1
SCHEMBL23748149 0.72 BRD4 (0.38) IDO1TDO2ALDH1A1MAPT
SCHEMBL477580 0.71 ACP3 (0.53) ATMKMT2AIDO1TDO2IDO2
SCHEMBL477602 0.71 ACP3 (0.53) ATMKMT2AIDO1TDO2IDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 CXCR5 1816/4885ATM 2710/4885KMT2A 1447/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP CXCR5 1703/4885ATM 3043/4885KMT2A 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.